Home > Insider Trading > Filing (0000899243-20-020730)

Filing Details

Accession Number:: 0000899243-20-020730
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-30 09:00:49
Reporting Period:: 2020-07-28

Accepted Time:: 2020-07-30 09:00:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1465914	I. Aaron Davis	C/O Iteos Therapeutics, Inc. 139 Main Street Cambridge MA 02142		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-28	2,943,568	$0.00	2,943,568	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	48,691	$0.00	48,691	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	1,401,448	$19.00	4,345,016	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2020-07-28	23,552	$19.00	72,243	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	9,593,086	$0.00	2,943,568	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	158,687	$0.00	48,691	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
These securities are owned directly by Boxer Capital, which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
These securities are owned directly by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
On July 28, 2020, Boxer Capital purchased 1,401,448 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering..
On July 28, 2020, MVA Investors purchased 23,552 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.